Market closed
Intra-Cellular Therapies/$ITCI
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Intra-Cellular Therapies
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
Ticker
$ITCI
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
610
ITCI Metrics
BasicAdvanced
$9.6B
Market cap
-
P/E ratio
-$0.86
EPS
1.00
Beta
-
Dividend rate
Price and volume
Market cap
$9.6B
Beta
1
52-week high
$89.41
52-week low
$52.88
Average daily volume
588K
Financial strength
Current ratio
7.656
Quick ratio
6.936
Long term debt to equity
1.18
Total debt to equity
1.547
Management effectiveness
Return on assets (TTM)
-7.44%
Return on equity (TTM)
-9.90%
Valuation
Price to revenue (TTM)
14.847
Price to book
8.38
Price to tangible book (TTM)
8.38
Price to free cash flow (TTM)
-144.842
Growth
Revenue change (TTM)
46.08%
Earnings per share change (TTM)
-47.18%
3-year revenue growth (CAGR)
105.63%
3-year earnings per share growth (CAGR)
-35.52%
What the Analysts think about ITCI
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Intra-Cellular Therapies stock.
ITCI Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ITCI Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ITCI News
AllArticlesVideos
Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress
GlobeNewsWire·18 hours ago
Intra-Cellular's schizophrenia drug meets main goal in late-stage trial
Reuters·3 days ago
Intra-Cellular Therapies, Inc. (ITCI) Q3 2024 Earnings Call Transcript
Seeking Alpha·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Intra-Cellular Therapies stock?
Intra-Cellular Therapies (ITCI) has a market cap of $9.6B as of November 08, 2024.
What is the P/E ratio for Intra-Cellular Therapies stock?
The price to earnings (P/E) ratio for Intra-Cellular Therapies (ITCI) stock is 0 as of November 08, 2024.
Does Intra-Cellular Therapies stock pay dividends?
No, Intra-Cellular Therapies (ITCI) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next Intra-Cellular Therapies dividend payment date?
Intra-Cellular Therapies (ITCI) stock does not pay dividends to its shareholders.
What is the beta indicator for Intra-Cellular Therapies?
Intra-Cellular Therapies (ITCI) has a beta rating of 1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.